publication date: Oct. 1, 2014


html Chemotherapy.html

Fidaxomicin for CDI Therapy More Cost-Effective Than Vancomycin, Study Says

Overall treatment costs for cancer patients with clostridium difficile infection, based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of approximately $7,000 per patient.

Patients who have received chemotherapy and those with solid tumors can be particularly susceptible to CDI due to their long hospital stays and exposure to many antibiotics and chemotherapeutic agents. These patients are also prone to recurrent episodes of CDI. Hospital patients with CDI are up to three times more likely to die in hospital (or within a month of infection) than those without CDI.

CDI results from infection of the internal lining of the colon by C. difficile bacteria. Patients typically develop CDI after the use of broad-spectrum antibiotics that disrupt normal bowel flora, allowing C. difficile bacteria to flourish.

This pharmacoeconomic model combined data from a study exploring the resolution of CDI in cancer patients treated with either fidaxomicin or vancomcyin and a recent cost-of-illness analysis on CDI conducted at the University Hospital of Cologne.

The analysis explored direct cost parameters including drug costs, treatment on the general ward and intensive care unit as well as microbiological diagnostics for clostridium difficile.

Mean overall treatment costs per patient treated with fidaxomicin and vancomycin were approximately $28,000 and $35,000, respectively. The lower costs were primarily due to the significantly lower rate of recurrence in patients treated with fidaxomicin.

Data were presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy.

“Patients with cancer represent a vulnerable population who are … Continue reading CCL Sept – Chemotherapy

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.